That is actually not bad ideology - staying away from oncology and in my case ALZ. Having said that I think OSTX is further along and will be having discussions with the FDA for possible approval of OST-HER2 with only having to enroll patients in a follow-up study. As long as they don't get the rug pullout out from under them like AMRN and Anchor.
Market Data 
Markets 
AI
